Table 2 Potential inhibitors of the PI3K/AKT/mTOR pathway available for targeting AKT.

 AKT

MK-2206

II Completed

Colorectal neoplasms

With AZD624

NCT01333475

II Completed

PANCREAS

Neuroendocrine

Monotherapy

NCT01169649

II Completed

Ovarian sarcoma

Recurrent fallopian tube carcinoma, recurrent ovarian carcinoma

Recurrent primary peritoneal carcinoma

Monotherapy

NCT01283035

II Completed

Recurrent nasopharyngeal carcinoma

Monotherapy

NCT01370070

II Completed

Diffuse large B-cell lymphoma

Monotherapy

NCT01481129

I/II Completed

Chronic lymphocytic leukemia

Recurrent small Lymphocytic lymphoma

Refractory chronic Lymphocytic leukemia

With Bendamustine Hydrochloride, Rituximab

NCT01369849

II Completed

Pancreatic acinar cell carcinoma

Pancreatic ductal Adenocarcinoma

Recurrent pancreatic carcinoma

With Fluorouracil, Oxaliplatin, Selumetinib

NCT01658943

II Ongoing

Carcinoma, non-small-cell lung

Carcinoma, small-cell lung carcinoma, thymic

With AZD6244, Lapatinib, Erlotinib, Sunitinib

NCT01306045

II Completed

Lung cancer

With Erlotinib, AZD6244, Sorafenib

NCT01248247

II Ongoing

Breast neoplasms

Breast cancer

Angiosarcoma

TNBC-triple-negative breast cancer…

With AMG 386, AMG 479, MK-2206, AMG 386 and Trastuzumab, T-DM1 and Pertuzumab…

NCT01042379

BAY1125976

I Completed

Neoplasms

Monotherapy

NCT01915576

TAS‑117

II Completed

Solid tumor, adult

Monotherapy

NCT03017521

II Ongoing

Advanced or metastatic solid tumors irrespective of gene alterations

Advanced or metastatic solid tumors with germline PTEN inactivating mutations

Monotherapy

NCT04770246

MSC2363318A

I Completed

Solid tumor

With Trastuzumab, Tamoxifen

NCT01971515

AZD5363 (Capivasertib)

I Ongoing

Solid tumor, adult

With Olaparib, Durvalumab

NCT03772561

I Ongoing

Breast cancer

Prostate cancer

Advanced solid tumors

With Enzalutamide, Fulvestrant

NCT03310541

I/II Completed

Prostate cancer

With Placebo

NCT02121639

II Completed

Advanced gastric cancer

With Paclitaxel

NCT02451956

I/II Ongoing

Estrogen receptor-positive breast cancer

With Fulvestrant

NCT01992952

I/II Completed

Advanced or metastatic breast cancer

ER+ve advanced or metastatic breast cancer

With Paclitaxel

NCT01625286

I Completed

Prostate cancer

With Capivasertib, Enzalutamide, Abiraterone

NCT04087174

I Completed

Advanced solid tumors

With Capivasertib, Paclitaxel

NCT04742036

III Ongoing

Triple-negative breast neoplasms

With Capivasertib, Paclitaxel

NCT03997123

II Ongoing

Intracranial meningioma

Recurrent meningioma

NF2 gene mutation

With Vismodegib, GSK2256098, Capivasertib, Abemaciclib

NCT02523014

II Ongoing

Advanced breast cancer

With Fulvestrant, Neratinib, AZD5363, Olaparib, AZD6738

NCT03182634

I/II Ongoing

Triple-negative breast neoplasms

With Durvalumab, Capivasertib, Oleclumab, Paclitaxe, Trastuzumab deruxtecan, Datopotamab deruxtecan

NCT03742102

II Ongoing

Anatomic stage IV breast cancer AJCC v8

Metastatic triple-negative breast carcinoma

With Capivasertib, Ceralasertib, Olapari, Selumetinib

NCT03801369

Uprosertib

I/II Ongoing

Hematopoietic and lymphoid cell neoplasm

Locally advanced malignant solid neoplasm

Locally advanced melanoma

Metastatic malignant solid neoplasm…

With Dabrafenib Mesylate, Trametinib Dimethyl Sulfoxide

NCT01902173

Ipatasertib

I Ongoing

Metastatic breast cancer

With Trastuzumab, Pertuzumab

NCT04253561

I Ongoing

Head and neck carcinoma of unknown primary

Locally advanced head and neck squamous cell carcinoma…

With Cisplatin

NCT05172245

I Ongoing

Solid tumors

Monotherapy

NCT04341259

II Ongoing

NSCLC stage IV

NSCLC stage IIIB

Monotherapy

NCT04467801

II Ongoing

Triple-negative breast cancer

With Capecitabine, Eribulin, Carboplatin, Gemcitabine

NCT04464174

I/II Ongoing

Endometrial endometrioid adenocarcinoma

With Megestrol Acetate

NCT05538897

II Ongoing

Breast cancer

With Fulvestrant, Palbociclib, CDK4/6 Inhibitor

NCT04920708

I Ongoing

Castration-resistant prostatic cancer

With Atezolizumab, Docetaxel

NCT04404140

II Ongoing

Head and neck squamous cell carcinoma

With Pembrolizumab

NCT05172258

I/II Ongoing

Solid tumor

Glioblastoma multiforme

Prostate cancer

Metastatic

With Atezolizumab

NCT0367378

II Completed

Breast cancer

With Paclitaxel

NCT02301988

II Ongoing

Locally advanced malignant Solid neoplasm

Metastatic malignant solid Neoplasm

Unresectable malignant solid Neoplasm

With Paclitaxel

NCT05554380

III Ongoing

Breast cancer

With Paclitaxel, Placebo

NCT03337724

II Completed

Gastric cancer

With Leucovorin, 5-Fluorouracil, Oxaliplatin

NCT01896531

III Ongoing

Breast cancer

With Fulvestrant, Palbociclib

NCT04060862

III Ongoing

Breast cancer

With Fulvestrant

NCT04650581

III Ongoing

Triple-negative breast cancer

With Atezolizumab, Paclitaxel

NCT04177108

II Ongoing

Gastric adenocarcinoma

With Atezolizumab, Bevacizumab

NCT04739202

II Ongoing

Breast cancer

With Atezolizumab Injection, Pertuzuma, Trastuzumab, Bevacizumab,

NCT05180006

II Ongoing

Breast cancer

Estrogen receptor-positive breast cancer

With Atezolizumab, Cobimetinib, Bevacizumab

NCT03395899

II Ongoing

Triple-negative breast cancer

Residual cancer

Circulating tumor DNA

With Atezolizumab, Sacituzumab, govitecan

NCT04434040

I/II Ongoing

Endometrial cancer

With Atezolizumab, Bevacizumab, Talazoparib, Trastuzumab, emtansine, Tiragolumab

NCT04486352

I/II Ongoing

Carcinoma, non-small-cell lung

With Atezolizumab, Cobimetinib, RO6958688, Docetaxel, CPI-444, Pemetrexed, Carboplatin, Gemcitabine…

NCT03337698